<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01351740</url>
  </required_header>
  <id_info>
    <org_study_id>H10-03255</org_study_id>
    <secondary_id>H10-03255</secondary_id>
    <nct_id>NCT01351740</nct_id>
  </id_info>
  <brief_title>Switch to Unboosted Atazanavir With Tenofovir Study</brief_title>
  <acronym>SUAT</acronym>
  <official_title>Switch to Unboosted Atazanavir With Tenofovir (SUAT) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A drug-drug interaction between the anti-HIV drugs tenofovir DF (TDF) and atazanavir (ATZ)&#xD;
      results in lower ATZ plasma levels when the drugs are given together, particularly in&#xD;
      patients not taking ritonavir to boost ATZ levels. Lower plasma drug levels may make the&#xD;
      anti-HIV regimen less effective in controlling the HIV virus levels in the blood. For this&#xD;
      reason, current treatment guidelines recommend that ATZ always be boosted with ritonavir in&#xD;
      regimens also containing TDF. However, withdrawal of ritonavir is often desirable given the&#xD;
      tolerability and toxicity issues with this agent, even at the low dose (100 mg daily) used to&#xD;
      boost ATZ. For example, ritonavir can cause stomach upset, nausea, diarrhea, high cholesterol&#xD;
      levels, and liver enzyme abnormalities.&#xD;
&#xD;
      However, there is evidence that plasma ATZ levels may not predict treatment success on&#xD;
      unboosted ATZ regimens, particularly among people whose plasma HIV virus is already under&#xD;
      control and unboosted ATZ is being used as a maintenance strategy. In the BC Centre for&#xD;
      Excellence in HIV/AIDS Drug Treatment Program (DTP), nearly 100 patients originally treated&#xD;
      with ritonavir-boosted ATZ + TDF (+ FTC or 3TC) are receiving successful maintenance therapy&#xD;
      with unboosted ATZ and the same TDF-based backbone.&#xD;
&#xD;
      The study will examine the hypothesis that switching to maintenance therapy with unboosted&#xD;
      ATZ 400mg daily will have similar 48-week virologic efficacy to continuing ATZ/ritonavir&#xD;
      300/100mg daily among HIV-infected adults with stable viral load suppression on regimens&#xD;
      comprising ATZ/ritonavir 300/100mg daily with TDF plus either FTC or 3TC, despite potentially&#xD;
      lower ATZ trough levels with the unboosted regimen. In other words, patients whose HIV viral&#xD;
      load is undetectable while receiving TDF (+FTC or 3TC) and ATZ/ritonavir will continue to&#xD;
      maintain an undetectable viral load after switching to unboosted ATZ without ritonavir, in&#xD;
      the same proportions as those continuing on their boosted ATZ/ritonavir regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following a screening visit to establish study eligibility, eligible consenting subjects will&#xD;
      be randomized 1:1 to one of the two treatment arms (switch to unboosted ATZ or continue&#xD;
      ritonavir-boosted ATZ). Randomized open-label treatment will commence following study&#xD;
      procedures at baseline. Participants will be assessed at baseline and at weeks 4, 8, 12, 24,&#xD;
      36, and 48. On-study evaluations will include assessment of adverse clinical events and&#xD;
      medication changes; blood tests for HIV viral load, CD4 cell count, standard safety&#xD;
      parameters, fasting lipids and glucose, and pregnancy testing (if applicable); and urine&#xD;
      tests for urinalysis and albumin to creatinine ratio. In addition, a serum sample will be&#xD;
      stored at each visit for possible future testing. A timed plasma sample for measurement of&#xD;
      pre-dose trough ATZ levels will be obtained once per subject at 4-8 weeks. Quality of life&#xD;
      will be assessed by completion of the MOS-HIV questionnaire at baseline and every 12 weeks.&#xD;
      Adherence will be assessed based on prescription refill data.&#xD;
&#xD;
      In case of protocol-defined virologic failure, a plasma sample for ATZ trough level will be&#xD;
      collected, and genotypic resistance testing will be performed on plasma samples with viral&#xD;
      load &gt;250 copies/mL. Subjects with confirmed virologic failure will be asked to come to the&#xD;
      clinic and will have their HIV treatment changed to a more effective regimen, selected based&#xD;
      on the results of genotypic testing, as soon as possible.&#xD;
&#xD;
      The anticipated rate of confirmed virologic failure in the control arm is no more than 15%&#xD;
      over the 48 weeks of the study. Once at least 20 subjects have been assigned to the&#xD;
      experimental (switch) treatment arm, if the observed confirmed virologic failure rate in the&#xD;
      experimental arm is greater than twice this rate, i.e. &gt;30%, at any time during the study,&#xD;
      the study will be stopped. At this time, subjects in the experimental arm will be reassessed&#xD;
      as soon as possible and will resume ritonavir-boosted atazanavir or other effective HIV&#xD;
      therapy as appropriate. The failure rate will be reassessed at a minimum after each 20&#xD;
      subjects are enrolled into the experimental (switch) arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportions of Subjects Experiencing Virologic Failure by Randomized Treatment Arm</measure>
    <time_frame>at or before 48 weeks.</time_frame>
    <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportions of Subjects in Each Randomized Treatment Arm With Atazanavir Trough Levels Below 150ng/mL</measure>
    <time_frame>1 month (4-8 weeks)</time_frame>
    <description>Therapeutic drug monitoring (TDM) to determine atazanavir trough plasma level will be performed once on all subjects at 4-8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Experiencing Virologic Failure by Results of 1-month TDM</measure>
    <time_frame>at or before 48 weeks</time_frame>
    <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart. Comparison will be made between subjects with 1-month (4-8 week) on-study atazanavir trough levels &lt;150ng/mL and those with 1-month (4-8 week) on-study atazanavir trough levels &gt;150ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Subjects Experiencing Virologic Failure by Randomized Treatment Arm</measure>
    <time_frame>at or before 24 weeks.</time_frame>
    <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Experiencing Virologic Failure by Results of 1-month TDM</measure>
    <time_frame>at or before 24 weeks</time_frame>
    <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart. Comparison will be made between subjects with 1-month (4-8 week) on-study atazanavir trough levels &lt;150ng/mL and those with 1-month (4-8 week) on-study atazanavir trough levels &gt;150ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 Cell Count Changes (Absolute and Fraction)</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Comparison will be made between randomized treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Clinical and Laboratory Adverse Events)</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Serious adverse events and discontinuations will be compared between randomized treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Serum Bilirubin Levels</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Comparison will be made between randomized treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Parameters</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Comparison will be made between randomized treatment arms with respect to changes in fasting lipids and glucose, highly sensitive C-reactive protein [hsCRP], and apolipoprotein [apo]B, and proportions of subjects developing abnormalities or crossing predefined limits (e.g. NCEP thresholds for lipids)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Assessed by MOS-HIV</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Changes in MOS-HIV scores from baseline will be compared between randomized treatment arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Switch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>switch to unboosted atazanavir 400mg daily with the same nucleoside (NRTI) backbone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>continue on current regimen of atazanavir/ritonavir 300mg/100mg with the same nucleoside (NRTI) backbone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atazanavir</intervention_name>
    <description>switch to unboosted atazanavir 400 mg daily</description>
    <arm_group_label>Switch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atazanavir/ritonavir</intervention_name>
    <description>Continue current regimen of atazanavir 300 mg/ ritonavir 100 mg daily</description>
    <arm_group_label>Continuation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HIV infected adults at least 19 years of age&#xD;
&#xD;
          2. Willing and able to provide informed consent to study participation&#xD;
&#xD;
          3. Currently receiving a regimen including atazanavir 300mg/ritonavir 100mg daily with&#xD;
             either tenofovir/emtricitabine (FTC) or tenofovir/lamivudine (3TC), for at least 3&#xD;
             months&#xD;
&#xD;
          4. Plasma viral load (VL) &lt;40 copies/mL for at least 2 consecutive measurements including&#xD;
             the screening value, and &lt; 150 copies/mL continuously for at least 3 months prior to&#xD;
             screening&#xD;
&#xD;
          5. Current regimen is first antiretroviral regimen, or if not first regimen, no evidence&#xD;
             of resistance to any nucleosides (NRTIs) or protease inhibitors (PIs) on previous&#xD;
             resistance tests&#xD;
&#xD;
          6. Any CD4&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant intolerance or toxicity with current regimen precluding regimen&#xD;
             continuation (e.g. intolerance/toxicity to ritonavir necessitating ritonavir&#xD;
             discontinuation)&#xD;
&#xD;
          2. pregnancy or breast-feeding&#xD;
&#xD;
          3. antiretroviral regimen including any nonnucleoside reverse transcriptase inhibitor&#xD;
             (nevirapine, efavirenz, or etravirine)&#xD;
&#xD;
          4. antiretroviral regimen including any protease inhibitor other than atazanavir and&#xD;
             ritonavir&#xD;
&#xD;
          5. concomitant treatment with proton pump inhibitors, rifampin, St. John's wort, or&#xD;
             garlic supplements. (Antacids and H2 receptor antagonists will be allowed provided&#xD;
             their dosing is separated from atazanavir administration by at least 2 and 10 hours,&#xD;
             respectively).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Harris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Health Care/ University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Immunodeficiency Clinic, St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.tandfonline.com/doi/full/10.1080/15284336.2016.1271503</url>
    <description>Journal article</description>
  </link>
  <results_reference>
    <citation>Harris M, Ganase B, Watson B, Hull MW, Guillemi SA, Zhang W, Saeedi R, Harrigan PR. Efficacy and safety of &quot;unboosting&quot; atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF. HIV Clin Trials. 2017 Jan;18(1):39-47. doi: 10.1080/15284336.2016.1271503. Epub 2017 Jan 9.</citation>
    <PMID>28067119</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>May 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2011</study_first_posted>
  <results_first_submitted>October 24, 2017</results_first_submitted>
  <results_first_submitted_qc>October 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2018</results_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Marianne Harris, MD</investigator_full_name>
    <investigator_title>Dr. Marianne Harris</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Switch</title>
          <description>switch to unboosted atazanavir 400mg daily with the same nucleoside (NRTI) backbone&#xD;
atazanavir: switch to unboosted atazanavir 400 mg daily</description>
        </group>
        <group group_id="P2">
          <title>Continuation</title>
          <description>continue on current regimen of atazanavir/ritonavir 300mg/100mg with the same nucleoside (NRTI) backbone&#xD;
atazanavir/ritonavir: Continue current regimen of atazanavir 300 mg/ ritonavir 100 mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Switch</title>
          <description>Switch to atazanavir 400 mg daily</description>
        </group>
        <group group_id="B2">
          <title>Continuation</title>
          <description>Remain on atazanavir/ritonavir 300mg/100 mg daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="42" upper_limit="52"/>
                    <measurement group_id="B2" value="46" lower_limit="39" upper_limit="53"/>
                    <measurement group_id="B3" value="47" lower_limit="40" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportions of Subjects Experiencing Virologic Failure by Randomized Treatment Arm</title>
        <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart.</description>
        <time_frame>at or before 48 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Switch</title>
            <description>Switch to atazanavir 400 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Continuation</title>
            <description>Remain on atazanavir/ritonavir 300mg/100mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportions of Subjects Experiencing Virologic Failure by Randomized Treatment Arm</title>
          <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportions of Subjects in Each Randomized Treatment Arm With Atazanavir Trough Levels Below 150ng/mL</title>
        <description>Therapeutic drug monitoring (TDM) to determine atazanavir trough plasma level will be performed once on all subjects at 4-8 weeks</description>
        <time_frame>1 month (4-8 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Switch</title>
            <description>Switch to atazanavir 400 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Continuation</title>
            <description>Remain on atazanavir/ritonavir 300mg/100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Proportions of Subjects in Each Randomized Treatment Arm With Atazanavir Trough Levels Below 150ng/mL</title>
          <description>Therapeutic drug monitoring (TDM) to determine atazanavir trough plasma level will be performed once on all subjects at 4-8 weeks</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Experiencing Virologic Failure by Results of 1-month TDM</title>
        <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart. Comparison will be made between subjects with 1-month (4-8 week) on-study atazanavir trough levels &lt;150ng/mL and those with 1-month (4-8 week) on-study atazanavir trough levels &gt;150ng/mL.</description>
        <time_frame>at or before 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportions of Subjects Experiencing Virologic Failure by Randomized Treatment Arm</title>
        <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart.</description>
        <time_frame>at or before 24 weeks.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Experiencing Virologic Failure by Results of 1-month TDM</title>
        <description>For the purposes of the study, virologic failure is defined as either regimen change for any reason, or plasma viral load &gt;400 copies/mL on 2 consecutive measurements &gt;2 weeks apart. Comparison will be made between subjects with 1-month (4-8 week) on-study atazanavir trough levels &lt;150ng/mL and those with 1-month (4-8 week) on-study atazanavir trough levels &gt;150ng/mL.</description>
        <time_frame>at or before 24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4 Cell Count Changes (Absolute and Fraction)</title>
        <description>Comparison will be made between randomized treatment arms.</description>
        <time_frame>24 and 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety (Clinical and Laboratory Adverse Events)</title>
        <description>Serious adverse events and discontinuations will be compared between randomized treatment arms</description>
        <time_frame>24 and 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Serum Bilirubin Levels</title>
        <description>Comparison will be made between randomized treatment arms.</description>
        <time_frame>24 and 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Parameters</title>
        <description>Comparison will be made between randomized treatment arms with respect to changes in fasting lipids and glucose, highly sensitive C-reactive protein [hsCRP], and apolipoprotein [apo]B, and proportions of subjects developing abnormalities or crossing predefined limits (e.g. NCEP thresholds for lipids)</description>
        <time_frame>24 and 48 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Assessed by MOS-HIV</title>
        <description>Changes in MOS-HIV scores from baseline will be compared between randomized treatment arms.</description>
        <time_frame>24 and 48 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Switch</title>
          <description>Switch to atazanavir 400 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Continuation</title>
          <description>Remain on atazanavir/ritonavir 300 mg/100 mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Marianne Harris</name_or_title>
      <organization>British Columbia Centre for Excellence in HIV/AIDS</organization>
      <phone>1-604-806-8771</phone>
      <email>mharris@cfenet.ubc.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

